TARA
Protara Therapeutics, Inc. Common Stock
stockNASDAQ
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.25 | 2026-09-28 | -17.08% | 0.532 |
| 1M | 3.94 | 2026-09-04 | -31.60% | 0.862 |
| 3M | 4.08 | 2026-07-06 | -33.95% | 1.212 |
| 6M | 5.07 | 2026-04-06 | -46.84% | 1.267 |
| 1Y | 4.87 | 2025-10-06 | -44.66% | 1.053 |
| 2Y | 1.79 | 2024-10-04 | +50.56% | — |
| 5Y | 6.46 | 2021-10-05 | -58.28% | 1.091 |
Protara Therapeutics, Inc. Common Stock (NASDAQ:TARA) stock price today is $2.70, and today's volume is 1,909,317. TARA is down 2.355% today. The 30 day average volume is 1.20M. TARA market cap is $159.26M with 59.10M shares outstanding.